Advertisement

A novel cysteine-sparing G73A mutation of NOTCH3 in a Chinese CADASIL family

  • Liyan Huang
  • Wei Li
  • Yi Li
  • Chaoyuan Song
  • Pin Wang
  • Hongchun Wang
  • Xiulian SunEmail author
Original Article
  • 82 Downloads

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic disease leading to stroke and vascular dementia. CADASIL is an inherited small blood vessel disease caused by mutations in the gene encoding the neurogenic locus notch homolog protein 3 (NOTCH3). NOTCH3 is large type I membrane receptor mainly expressed in vascular smooth muscle cells and pericytes. Most identified mutations result in insert or deletion of a cysteine residue within the EGF-like repeats. To date, some cases with a cysteine-sparing mutant have been described. Genetic analysis revealed a novel mutation in NOTCH3 in a CADASIL family. Molecular analysis revealed its potential pathogenic mechanism in causing CADASIL. In this paper, we present a Chinese family with a novel cysteine-sparing mutation in exon 3 (c.218G>C, p.G73A) of the NOTCH3 gene. Family carriers of the same mutation presented with symptoms and imaging abnormalities characteristic of CADASIL. The location of glycine 73 in between C5-C6 disulfide bond of EGF-like domain 1 shows high conservation from humans to zebra fish. It has previously been suggested that the aggregate-prone property of mutant NOTCH3 contributes to a cytotoxic effect in the pathogenic mechanism underlying CADASIL. Here, we investigated the pathogenic mechanism of the new mutation in vitro using HEK293 cells transfected with either a wild-type (WT) or c.218G>C (p.G73A) NOTCH3ECD plasmids, and we found p.G73A NOTCH3ECD was more prone to form aggregation and resistant to degradation. Moreover, the p.G73A NOTCH3ECD compromised cell viability by promoting apoptosis. Two known CADASIL mutants R133C and R75P showed similar results with G73A mutants. Our study here identified G73A as a new mutation in NOTCH3 to cause CADASIL and revealed that the G73A mutation and two known mutants R75P and R133C decreased NOTCH3 protein turnover and induced cell death.

Keywords

CADASIL NOTCH3 Apoptosis Stroke Dementia 

Abbreviations

ANOVA

analysis of variance

CADASIL

cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

CCK8

Cell Counting Kit-8

CHD

coronary heart disease

CHX

chlorhexidine

DAPI

4′,6′-diamino-2-phenylindole

DM

diabetes mellitus

DSL

Delta/Serrate/Lag-2

ECD

extracellular domain

ECM

extracellular matrix

EGF-like repeats

epidermal growth factor-like repeats

ER

endoplasmic reticulum

FCM

flow cytometry

FITC

fluorescein isothiocyanate

FLAIR

fluid-attenuated inversion recovery magnetic resonance imaging

GOM

granular osmiophilic material

HAMA

Hamilton Anxiety Scale

HEK293

human embryonic kidney 293 cells

ICD

intracellular domain

IGT

impaired glucose tolerance

MRI

magnetic resonance imaging

MMSE

mini-mental state examination

NOTCH3

neurogenic locus notch homolog protein 3

PBS

phosphate-buffered saline

PI

propidium iodide

SWI

susceptibility weighted imaging

UPR

unfolded protein response

VSMCs

vascular smooth muscle cells

MH

T2-weighted white matter hyperintensity

WT

wild type

Notes

Acknowledgements

We thank Dr. Weihong Song for his instructive suggestions.

Availability of data and materials

All data generated or analyzed during this study are included in this published article (and as supplement original data.pdf).

Author’s contributions

L. H. and X. S. designed the experiments and wrote the manuscript. W. L. collected the clinical data. L. H. performed the molecular studies. Y. L., C. S., P. W., and H. W. helped in preparing the materials. All authors read and approved the final manuscript.

Funding information

This study was supported by grants from NSFC (81771155) to Xiulian Sun and grants from Shandong Key Research Project (2018GSF118104) to Hongchun Wang.

Compliance with ethical standards

Ethical statements

Study protocols were approved by the Medical Ethical Committee of Qingdao Municipal Hospital (2016-002). All persons gave their informed consent prior to their inclusion in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

References

  1. 1.
    Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 9(7):689–701CrossRefGoogle Scholar
  2. 2.
    Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG (2009) Cadasil. Lancet Neurol. 8(7):643–653CrossRefGoogle Scholar
  3. 3.
    Takahashi K, Adachi K, Yoshizaki K, Kunimoto S, Kalaria RN, Watanabe A (2010) Mutations in NOTCH3 cause the formation and retention of aggregates in the endoplasmic reticulum, leading to impaired cell proliferation. Human molecular genetics. 19(1):79–89CrossRefGoogle Scholar
  4. 4.
    Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, Klonjkowski B, Berrou E, Mericskay M, Li Z, Tournier-Lasserve E, Gridley T, Joutel A (2004) Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 18(22):2730–2735CrossRefGoogle Scholar
  5. 5.
    Cognat E, Baron-Menguy C, Domenga-Denier V, Cleophax S, Fouillade C, Monet-Lepretre M et al (2014) Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss-of-function mechanism. Stroke. 45(3):842–849CrossRefGoogle Scholar
  6. 6.
    Ge W, Kuang H, Wei B, Bo L, Xu Z, Xu X, Geng D, Sun M (2014) A novel cysteine-sparing NOTCH3 mutation in a Chinese family with CADASIL. PLoS One. 9(8):e104533CrossRefGoogle Scholar
  7. 7.
    Louvi A, Artavanis-Tsakonas S (2012) Notch and disease: a growing field. Semin Cell Dev Biol. 23(4):473–480CrossRefGoogle Scholar
  8. 8.
    Fortini ME, Bilder D (2009) Endocytic regulation of Notch signaling. Curr Opin Genet Dev. 19(4):323–328CrossRefGoogle Scholar
  9. 9.
    Kopan R (2012) Notch signaling. Cold Spring Harb Perspect Biol 4(10)CrossRefGoogle Scholar
  10. 10.
    Meng H, Zhang X, Yu G, Lee SJ, Chen YE, Prudovsky I, Wang MM (2012) Biochemical characterization and cellular effects of CADASIL mutants of NOTCH3. PLoS One. 7(9):e44964CrossRefGoogle Scholar
  11. 11.
    Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssiere C et al (1997) Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 350(9090):1511–1515CrossRefGoogle Scholar
  12. 12.
    Monet M, Domenga V, Lemaire B, Souilhol C, Langa F, Babinet C, Gridley T, Tournier-Lasserve E, Cohen-Tannoudji M, Joutel A (2007) The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo. Human molecular genetics. 16(8):982–992CrossRefGoogle Scholar
  13. 13.
    Kitamoto T, Takahashi K, Takimoto H, Tomizuka K, Hayasaka M, Tabira T, Hanaoka K (2005) Functional redundancy of the Notch gene family during mouse embryogenesis: analysis of Notch gene expression in Notch3-deficient mice. Biochem Biophys Res Commun. 331(4):1154–1162CrossRefGoogle Scholar
  14. 14.
    Donahue CP, Kosik KS (2004) Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. Genomics. 83(1):59–65CrossRefGoogle Scholar
  15. 15.
    Monet-Lepretre M, Haddad I, Baron-Menguy C, Fouillot-Panchal M, Riani M, Domenga-Denier V et al (2013) Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. Brain : a journal of neurology. 136(Pt 6):1830–1845CrossRefGoogle Scholar
  16. 16.
    Rutten JW, Boon EM, Liem MK, Dauwerse JG, Pont MJ, Vollebregt E, Maat-Kievit AJ, Ginjaar HB, Lakeman P, van Duinen S, Terwindt GM, Lesnik Oberstein SA (2013) Hypomorphic NOTCH3 alleles do not cause CADASIL in humans. Hum Mutat. 34(11):1486–1489CrossRefGoogle Scholar
  17. 17.
    Joutel A (2011) Pathogenesis of CADASIL: transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature. Bioessays. 33(1):73–80CrossRefGoogle Scholar
  18. 18.
    Duering M, Karpinska A, Rosner S, Hopfner F, Zechmeister M, Peters N, Kremmer E, Haffner C, Giese A, Dichgans M, Opherk C (2011) Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. Human molecular genetics. 20(16):3256–3265CrossRefGoogle Scholar
  19. 19.
    Opherk C, Duering M, Peters N, Karpinska A, Rosner S, Schneider E, Bader B, Giese A, Dichgans M (2009) CADASIL mutations enhance spontaneous multimerization of NOTCH3. Human molecular genetics. 18(15):2761–2767CrossRefGoogle Scholar
  20. 20.
    Ihalainen S, Soliymani R, Iivanainen E, Mykkanen K, Sainio A, Poyhonen M et al (2007) Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Mol Med. 13(5-6):305–314CrossRefGoogle Scholar
  21. 21.
    Muino E, Gallego-Fabrega C, Cullell N, Carrera C, Torres N, Krupinski J et al (2017) Systematic review of cysteine-sparing NOTCH3 missense mutations in patients with clinical suspicion of CADASIL. International journal of molecular sciences 18(9)CrossRefGoogle Scholar
  22. 22.
    Vlachakis D, Tsaniras SC, Ioannidou K, Baumann M, Kossida S (2014) A series of NOTCH3 mutations in CADASIL; insights from 3D molecular modelling and evolutionary analyses. J Mol Biochem. 3:97–105Google Scholar
  23. 23.
    Wollenweber FA, Hanecker P, Bayer-Karpinska A, Malik R, Bazner H, Moreton F et al (2015) Cysteine-sparing CADASIL mutations in NOTCH3 show proaggregatory properties in vitro. Stroke. 46(3):786–792CrossRefGoogle Scholar
  24. 24.
    Zhu Y, Wang J, Wu Y, Wang G, Hu B (2015) Two novel mutations in NOTCH3 gene causes cerebral autosomal dominant arteriopathy with subcritical infarct and leucoencephalopathy in two Chinese families. Int J Clin Exp Pathol. 8(2):1321–1327PubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang Z, Yuan Y, Zhang W, Lv H, Hong D, Chen B, Liu Y, Luan X, Xie S, Wu S (2011) NOTCH3 mutations and clinical features in 33 mainland Chinese families with CADASIL. Journal of neurology, neurosurgery, and psychiatry. 82(5):534–539CrossRefGoogle Scholar
  26. 26.
    Chen S, Ni W, Yin XZ, Liu HQ, Lu C, Zheng QJ, Zhao GX, Xu YF, Wu L, Zhang L, Wang N, Li HF, Wu ZY (2017) Clinical features and mutation spectrum in Chinese patients with CADASIL: a multicenter retrospective study. CNS Neurosci Ther. 23(9):707–716CrossRefGoogle Scholar
  27. 27.
    Joutel A, Haddad I, Ratelade J, Nelson MT (2016) Perturbations of the cerebrovascular matrisome: a convergent mechanism in small vessel disease of the brain? J Cereb Blood Flow Metab. 36(1):143–157CrossRefGoogle Scholar
  28. 28.
    Yamamoto Y, Craggs LJ, Watanabe A, Booth T, Attems J, Low RW, Oakley AE, Kalaria RN (2013) Brain microvascular accumulation and distribution of the NOTCH3 ectodomain and granular osmiophilic material in CADASIL. J Neuropathol Exp Neurol. 72(5):416–431CrossRefGoogle Scholar
  29. 29.
    Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F, Godfrain C, Tournier-Lasserve E (2000) The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. The Journal of clinical investigation. 105(5):597–605CrossRefGoogle Scholar
  30. 30.
    Ghezali L, Capone C, Baron-Menguy C, Ratelade J, Christensen S, Ostergaard Pedersen L et al (2018) Notch3(ECD) immunotherapy improves cerebrovascular responses in CADASIL mice. Ann Neurol.Google Scholar
  31. 31.
    Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP (1999) The natural history of CADASIL: a pooled analysis of previously published cases. Stroke. 30(6):1230–1233CrossRefGoogle Scholar
  32. 32.
    Chabriat H, Tournier-Lasserve E, Vahedi K, Leys D, Joutel A, Nibbio A, Escaillas JP, Iba-Zizen MT, Bracard S, Tehindrazanarivelo A (1995) Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology. 45(6):1086–1091CrossRefGoogle Scholar
  33. 33.
    Vyshka G, Kruja J (2013) Clinical variability of the cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy phenotype in two siblings of a large family showing the same mutation. Int Med Case Rep J. 6:59–63CrossRefGoogle Scholar
  34. 34.
    Tan ZX, Li FF, Qu YY, Liu J, Liu GR, Zhou J, Zhu YL, Liu SL (2012) Identification of a known mutation in Notch 3 in familiar CADASIL in China. PLoS One. 7(5):e36590CrossRefGoogle Scholar
  35. 35.
    Dziewulska D, Sulejczak D, Wezyk M (2017) What factors determine phenotype of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)? Considerations in the context of a novel pathogenic R110C mutation in the NOTCH3 gene. Folia Neuropathol. 55(4):295–300CrossRefGoogle Scholar
  36. 36.
    Monet-Lepretre M, Bardot B, Lemaire B, Domenga V, Godin O, Dichgans M et al (2009) Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Brain : a journal of neurology. 132(Pt 6):1601–1612CrossRefGoogle Scholar
  37. 37.
    Adib-Samii P, Brice G, Martin RJ, Markus HS (2010) Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 41(4):630–634CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Liyan Huang
    • 1
  • Wei Li
    • 1
    • 3
  • Yi Li
    • 1
  • Chaoyuan Song
    • 5
  • Pin Wang
    • 4
  • Hongchun Wang
    • 6
  • Xiulian Sun
    • 2
    Email author
  1. 1.Department of NeurologyQilu Hospital of Shandong UniversityJinanChina
  2. 2.Brain Research InstituteQilu Hospital of Shandong UniversityJinanChina
  3. 3.Department of NeurologyQingdao Municipal HospitalQingdaoChina
  4. 4.Otolarygology Key Lab of National Health CommitteeQilu Hospital of Shandong UniversityJinanChina
  5. 5.Department of NeurologySecondary Hospital of Shandong UniversityJinanChina
  6. 6.Department of Clinical LaboratoryQilu Hospital of Shandong UniversityJinanChina

Personalised recommendations